Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data.

Koulaouzidis G, Koulaouzidis A, Marlicz W

Open source

DOI
10.21037/jgo-2026-1-0004
Published
2026 Apr 30
Container
Journal of gastrointestinal oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/jgo-2026-1-0004,
  title = {Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data.},
  author = {Koulaouzidis G and Koulaouzidis A and Marlicz W},
  year = {2026},
  journal = {Journal of gastrointestinal oncology},
  doi = {10.21037/jgo-2026-1-0004},
  url = {https://doi.org/10.21037/jgo-2026-1-0004}
}

RIS

TY  - JOUR
TI  - Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data.
AU  - Koulaouzidis G
AU  - Koulaouzidis A
AU  - Marlicz W
PY  - 2026
JO  - Journal of gastrointestinal oncology
DO  - 10.21037/jgo-2026-1-0004
UR  - https://doi.org/10.21037/jgo-2026-1-0004
ER  - 

APA

G, K., A, K., & W, M. (2026). Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data.. Journal of gastrointestinal oncology. https://doi.org/10.21037/jgo-2026-1-0004

Source records